bluebird bio (NASDAQ: BLUE) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare bluebird bio to related businesses based on the strength of its valuation, earnings, risk, analyst recommendations, dividends, profitability and institutional ownership.
Volatility & Risk
bluebird bio has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, bluebird bio’s competitors have a beta of 5.97, meaning that their average share price is 497% more volatile than the S&P 500.
Insider and Institutional Ownership
50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 3.9% of bluebird bio shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current recommendations for bluebird bio and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|bluebird bio Competitors||866||3222||11688||232||2.71|
bluebird bio presently has a consensus price target of $159.53, suggesting a potential downside of 13.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.77%. Given bluebird bio’s competitors stronger consensus rating and higher probable upside, analysts plainly believe bluebird bio has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares bluebird bio and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|bluebird bio||$6.16 million||-$263.50 million||-26.26|
|bluebird bio Competitors||$284.49 million||$33.78 million||81.73|
bluebird bio’s competitors have higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares bluebird bio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|bluebird bio Competitors||-5,310.77%||-218.27%||-39.48%|
bluebird bio competitors beat bluebird bio on 9 of the 12 factors compared.
bluebird bio Company Profile
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.